Research Paper Volume 15, Issue 16 pp 8204—8219
PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer
Figure 6. Verification of the prognostic value of PTPRD in immunotherapy. (A) Genomic landscape and clinical feature of PTPRD mutations in another ICIs cohort (MSK, Cancer Cell 2018). (B) The mutation of PTPRD was closely related to prognosis of LUAD with ICIs treatment. (C) PTPRD mutation was closely related to higher TMB in NSCLC.